All In Biotech

NDA 208183 · Lacer Pharma

Ultravate

Halobetasol Propionate · Topical

Last checked: Nov 20, 2026Latest source record: Aug 27, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Nov 6, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

28

6 Phase 3, 0 recruiting

FAERS reports

1,220

441 serious, 28 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 29, 2026.

Halobetasol Propionate Lotion 0.05% is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. Halobetasol Propionate Lotion 0.05% is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. ( 1 )

Mechanism: Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ULTRAVATE · HALOBETASOL PROPIONATE 0.05% · LOTION, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Halobetasol Propionate" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective253
  • psoriasis167
  • pruritus113
  • product use in unapproved indication87
  • rash80
  • pain72
  • fatigue68
  • arthralgia65
  • dry skin54
  • cough51
  • off label use50
  • skin exfoliation49

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200423
200523
200622
200714
20084
200911
20107
201115
201219
201321
201423
201549
201677
201752
201856
201960
202071
202176
2022146
2023233
202486
202570
202662

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 41 on PubMed

Sponsor: Lacer Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.